Year: 2026
Type: preprint
Abstract: Monobodies (Mobs) are a class of immunoglobulin (Ig)-like proteins that have emerged as promising therapeutic scaffolds for applications ranging from antiviral therapy to cancer treatment. Unlike conventional monoclonal antibodies (mAbs), Mobs can be readily expressed in Escherichia coli at high yields, offering important advantages in overall developability. However, discovering antigen-specific Mobs with high binding affinity traditionally requires screening large, randomized in vitro libraries. To optimize Mob discovery, we developed MobGen, a computational pipeline for de novo design of Mob binders against viral antigens. As a proof of concept, we generated Mobs that bind the SARS-CoV-2 Spike glycoprotein Receptor Binding Domain (RBD). Subsequent in silico optimization improved production yield, thermal and conformational stability, binding affinity, and antiviral activity, demonstrating a promising approach for rapidly developing antibody-like molecules that target viral entry. These findings highlight MobGen’s potential for de novo design of Mobs against emerging viruses with pandemic potential.
Authors: Pedro Moreira, Shuhao Xiao, Carlota J.F. Conceição, Marta Alenquer, Diogo H. Silva, Mariana Parada, Madalena C. Marques, Joseph Schmidt, Carolina C. Buga, Christine Cruz-Oliveira, Jéssica Rodrigues, Marta Pires de Miranda, Beatriz Vieira-da-Silva, Ye Wei, Javier Collado, María Jesús Rodríguez-Espinosa, Rocío Arranz, Sandrine Georgeon, César Santiago, José María Valpuesta, Ana S. Veiga, Miguel A.R.B. Castanho, Isabel A. Abreu, Maria João Amorim, João B. Vicente, Bruno E. Correia, Cláudio M. Soares, Diana Lousa
Institutions: Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, University of Minho, École Polytechnique Fédérale de Lausanne, Universidade Católica Portuguesa, University of Lisbon, Gulbenkian Institute for Molecular Medicine, City University of Hong Kong, Centro Nacional de Biotecnología
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: iNOVA4Health - Programa em Medicina Translacional (NMS, iBET, IPOLFG, ITQB e NIMSB), G3027892398, G4516981482, iMM-CARE: BOOSTING CLINICAL RESEARCH FOR THE BENEFIT OF SOCIETY, iNOVA4Health - Programa em Medicina Translacional (NMS, iBET, IPOLFG, ITQB e NIMSB), Instituto Gulbenkian de Medicina Molecular, G5015181383, Ciências da Vida para um Futuro Saudável e Sustentável, Instituto de Medicina Molecular João Lobo Antunes, iNOVA4Health - Programa em Medicina Translacional (NMS, iBET, IPOLFG, ITQB e NIMSB), A computational pipeline for the development of tailored biopharmaceuticals targeting viral fusion peptides, G6608505710, G6625891779, G7596775681, Evolvable and rapidly adaptable monobodies: a broad-spectrum antiviral platform, Microbiologia Molecular, Estrutural e Celular – Instituto de Tecnologia Química e Biológica António Xavier, G886374, G9001171393
OpenAlex ID: W7234242630
